200% Gain In One Day - Why Is Heart Failure Focused BioCardia Stock Soaring Today?

The FDA approved BioCardia Inc's BCDA Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure. The currently ongoing CardiAMP Heart Failure trial has completed enrollment, and the final data analyses are anticipated to be reported in Q4 2024.…#fda #biocardiainc #bcda
Source: Reuters: Health - Category: Consumer Health News Source Type: news